"Partnership or corporate action could come at anytime.... we know that Johnson&Johnson have a recent history of significant action in the cardiac space. We know also that Medtronic could view acquiring or partnering with DurAVR could mean that they take over as market leader from Edwards. We know that Edwards must see us as a serious threat to their companies TAVR division and this could incentivise them to buy or partner with us..... all interesting scenarios which could see significant corporate action"
Will everyone ease up on putting all their eggs in this basket - its just speculation and hopium at this stage and as yet has zero traction that we as shareholders know about anyways. We need to see a more fundamental investment thesis factors, capital raising pathway to $$...WP give us something to analyse and consider for new investors outside of "trust me bro, we're making incumbents nervous..." FFS.
AVR Price at posting:
$20.20 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)